Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Average Rating of “Hold” by Analysts

Cytek Biosciences, Inc. (NASDAQ:CTKB) has been assigned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $5.50.

A number of brokerages have commented on CTKB. TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a research note on Thursday, January 8th. Piper Sandler cut their price target on Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Morgan Stanley began coverage on Cytek Biosciences in a research report on Monday, December 1st. They set an “equal weight” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research report on Monday, December 29th. Finally, Zacks Research cut Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th.

Institutional Trading of Cytek Biosciences

Several hedge funds have recently bought and sold shares of the company. Federated Hermes Inc. lifted its stake in shares of Cytek Biosciences by 150.9% in the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after acquiring an additional 4,343 shares during the period. SBI Securities Co. Ltd. increased its stake in shares of Cytek Biosciences by 99.6% during the fourth quarter. SBI Securities Co. Ltd. now owns 5,010 shares of the company’s stock valued at $25,000 after acquiring an additional 2,500 shares during the period. Captrust Financial Advisors acquired a new position in shares of Cytek Biosciences during the second quarter valued at approximately $43,000. CIBC Bancorp USA Inc. bought a new stake in Cytek Biosciences during the third quarter worth approximately $43,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Cytek Biosciences in the second quarter worth approximately $52,000. 69.46% of the stock is currently owned by institutional investors.

Cytek Biosciences Stock Performance

Shares of NASDAQ:CTKB opened at $4.48 on Monday. The company’s fifty day moving average is $4.95 and its two-hundred day moving average is $4.56. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $6.18. The stock has a market capitalization of $572.81 million, a price-to-earnings ratio of -8.78 and a beta of 1.31.

Cytek Biosciences (NASDAQ:CTKB) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.36). Cytek Biosciences had a negative net margin of 33.02% and a negative return on equity of 7.70%. The business had revenue of $62.14 million during the quarter, compared to analyst estimates of $58.80 million. Sell-side analysts expect that Cytek Biosciences will post -0.06 EPS for the current fiscal year.

Key Headlines Impacting Cytek Biosciences

Here are the key news stories impacting Cytek Biosciences this week:

• Positive Sentiment: Revenue beat and record top-line: Cytek reported Q4 revenue of $62.14M, above consensus (~$58.8M) and commentary described record revenue despite challenges — a sign demand for its flow‑cytometry products remains intact. Article Title
• Positive Sentiment: FY2026 revenue guidance in a wide range ($205M–$212M) is broadly in line with street estimates (consensus ~$207.4M), giving some direction on growth expectations for the year. Article Title
• Neutral Sentiment: Earnings materials and transcript released — these provide management color on margin dynamics, headcount/cost actions and product rollout timelines that investors will parse for recovery signs. Earnings Presentation
• Neutral Sentiment: Full earnings call transcript is available for detail on items affecting profitability (one‑time charges, FX, inventory). Investors will judge whether margin headwinds are transitory. Call Transcript
• Negative Sentiment: Large EPS miss and continued unprofitability: CTKB reported a loss per share (reported –$0.34) well below the ~$0.02 consensus, and the company shows a negative net margin (~‑6.5%) and negative ROE — key reasons for downward pressure on the stock. Earnings Summary
• Negative Sentiment: Conflicting EPS/earnings summaries from outlets (some note a small loss vs street) add uncertainty and may amplify short‑term volatility as analysts update models. Zacks Article
• Neutral Sentiment: Short interest data in the feed appears unreliable/zeroed out (NaN/0) and likely isn’t a meaningful driver today. Short Interest Note

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.